North Central London Formulary


	North Central London Joint Formulary

Search

Formulary Chapter 9: Nutrition and blood - Full Chapter

09.09

Unlicensed Medicines / Significant off-label use

Azathioprine
(Haematology)

Formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.

Provider notes

NMUH:
RFL:

Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)

RNOH:

Non-formulary

UCLH:
WH:

Ciclosporin
(Haematology)

Formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.

Provider notes

NMUH:
RFL:

Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)

RNOH:

Non-formulary

UCLH:
WH:

Cyclophosphamide tablets
(Haematology)

Formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.

Provider notes

NMUH:
RFL:

Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)

RNOH:

Non-formulary

UCLH:
WH:

Danazol
(Haematology)

Formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.

Provider notes

NMUH:
RFL:

Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)

RNOH:

Non-formulary

UCLH:
WH:

Eculizumab infusion
(Hyperhaemolysis)

Formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.

Approved for 2^nd line management of Delayed Haemolytic Transfusion Reactions [DHTRs] hyperhaemolysis in adult Sickle Cell and β-thalassaemia patients who have not responded to IVIG and steroids (pending internal funding approval; JFC July 2019)

Provider notes

NMUH:

Non-formulary

RFL:

Non-formulary

RNOH:

Non-formulary

UCLH:
- Restricted to haematology. UMC to be informed of each patient. Funding agreed for 1 patient per annum.
WH:

Non-formulary

Mycophenolate mofetil
(Haematology)

Formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.

Provider notes

NMUH:
RFL:

Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)

RNOH:

Non-formulary

UCLH:
WH:

....

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs

Homecare

Traffic Light Status Information

Status	Description
	Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised. Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC. Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.
	Medicines which should normally be prescribed by specialists only (hospital only). For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care. See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf
	Medicines not recommended for routine use in primary or secondary care. Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.